Effect of Rebound Pain on Postoperative Intensive Care Delirium in Patients Undergoing Hip Surgery With Peripheral Nerve Block

May 12, 2026 updated by: HASAN ŞENAY, Konya City Hospital

Effect of Rebound Pain on Postoperative Intensive Care Delirium in Patients Undergoing Hip Surgery With Peripheral Nerve Block: A Prospective Observational Study

Postoperative delirium is a significant and commonly encountered complication in patients undergoing hip surgery, particularly among the elderly. Postoperative delirium is associated with serious consequences, including prolonged intensive care unit stay, increased complication rates, higher mortality risk, and rising healthcare costs.

The incidence of Postoperative delirium after hip fracture surgery has been reported to range between 13% and 55.9%, indicating a substantial clinical burden.

Effective postoperative pain control is critical not only for maintaining quality of life but also for preserving cognitive well-being. In this context, peripheral nerve blocks are frequently used for pain management following hip surgery.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Postoperative delirium is a significant and commonly encountered complication in patients undergoing hip surgery, particularly among the elderly. Postoperative delirium is associated with serious consequences, including prolonged intensive care unit stay, increased complication rates, higher mortality risk, and rising healthcare costs.

The incidence of Postoperative delirium after hip fracture surgery has been reported to range between 13% and 55.9%, indicating a substantial clinical burden.

Effective postoperative pain control is critical not only for maintaining quality of life but also for preserving cognitive well-being. In this context, peripheral nerve blocks are frequently used for pain management following hip surgery.

In recent years, the Pericapsular Nerve Group block and the supra-inguinal fascia iliaca block have gained attention as regional anesthesia techniques that provide effective analgesia by targeting the nerve branches innervating the anterior capsule of the hip joint.

Study Type

Observational

Enrollment (Estimated)

90

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

We conducted a pilot study on 20 patients using the 'goodness-of-fit tests: contingency tables' test with G Power software. In our study, the incidence of rebound pain was 40%, and postoperative delirium developed in 50% of patients with rebound pain, compared to 8.3% in patients without rebound pain.

Based on these data, an effect size of 0.356 was found, and an analysis was conducted using α=0.05, 90% power.

The sample size was calculated as 83 patients. Considering the dropout rate, a total of 90 patients (36 patients with rebound pain and 54 patients without rebound pain) were calculated to be included in the study.

Description

Inclusion Criteria:

  • Patients aged 18-80
  • ASA I-III risk groups
  • Undergoing elective hip surgery

Exclusion Criteria:

  • Preoperative history of delirium, dementia, or major neurological disease
  • Present cognitive impairment or severe hearing or visual impairment that could affect pain assessment
  • Development of mechanical ventilation requirement in the intensive care unit; Need for bilateral hip surgery
  • Failure to provide meaningful analgesia after block application due to surgical pain outside the scope of the block
  • Patient's inability to complete the pain diary during postoperative follow-up;
  • Urgent hip surgery
  • Voluntary failure to give consent or request to withdraw from the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of delirium
Time Frame: 72 hours
The incidence of delirium will be evaluated in the first 72 hours postoperatively in the intensive care unit.
72 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Konya City Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 12, 2026

Primary Completion (Estimated)

December 25, 2026

Study Completion (Estimated)

December 25, 2026

Study Registration Dates

First Submitted

December 8, 2025

First Submitted That Met QC Criteria

December 8, 2025

First Posted (Actual)

December 19, 2025

Study Record Updates

Last Update Posted (Actual)

May 14, 2026

Last Update Submitted That Met QC Criteria

May 12, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • Rebound pain

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe